"
Team:MIT/testhomepage
From 2014.igem.org
(Difference between revisions)
(Created page with "{{MIT-header}}") |
|||
| (2 intermediate revisions not shown) | |||
| Line 1: | Line 1: | ||
| - | {{MIT | + | {{Team:MIT/template1}} |
| + | |||
| + | <html> | ||
| + | <head> | ||
| + | </head> | ||
| + | <body style="font-family:Verdana, Geneva, sans-serif;"> | ||
| + | <table style="background-color:transparent; width:95%" align="center"> | ||
| + | |||
| + | <tr> <td> <p> </p> </td> </tr> | ||
| + | |||
| + | <tr> | ||
| + | <td> <h3 style="color:black"> Alzheimer's disease affects the lives of millions. </h3> </td> | ||
| + | </tr> | ||
| + | |||
| + | <tr> <td> <p> </p> </td> </tr> | ||
| + | |||
| + | <tr> | ||
| + | <td> | ||
| + | <table style="background-color:transparent; outline: solid black medium; width:60%" align="center"> | ||
| + | <tr> | ||
| + | <td align="center"> <img src="https://static.igem.org/mediawiki/2014/5/55/MIT_2014_IconPlaceHolder.png" width="90%"> </img> </td> | ||
| + | <td align="center"> <img src="https://static.igem.org/mediawiki/2014/5/55/MIT_2014_IconPlaceHolder.png" width="90%"> </img> </td> | ||
| + | <td align="center"> <img src="https://static.igem.org/mediawiki/2014/5/55/MIT_2014_IconPlaceHolder.png" width="90%"> </img> </td> | ||
| + | </tr> | ||
| + | <tr> | ||
| + | <td> <p align="center"> Neurodegenerative disease </p> </td> | ||
| + | <td> <p align="center"> 6th leading cause of death </p> </td> | ||
| + | <td> <p align="center"> No cure </p> </td> | ||
| + | </tr> | ||
| + | </table> | ||
| + | </td> | ||
| + | </tr> | ||
| + | |||
| + | <tr> <td> <h3> </h3> </td> </tr> | ||
| + | |||
| + | <tr> | ||
| + | <td> <p> Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery. | ||
| + | </p> </td> | ||
| + | </tr> | ||
| + | |||
| + | <tr> <td> <h3> </h3> </td> </tr> | ||
| + | |||
| + | </table> | ||
| + | </body> | ||
Latest revision as of 15:58, 5 October 2014
|
|
social media links |
| Introduction
|
Results
|
Project | Parts
|
Methods
|
Human Practices
|
About us
|
Modeling
|
Notebook
|
Safety
|
Attributions
|
|
| ||||||
Alzheimer's disease affects the lives of millions. |
||||||
|
| ||||||
|
||||||
| | ||||||
| Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery. |
||||||
| |
